Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $49.87 USD
Change Today -0.17 / -0.34%
Volume 835.9K
LCI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

lannett co inc (LCI) Snapshot

Open
$50.00
Previous Close
$50.04
Day High
$50.30
Day Low
$48.81
52 Week High
04/13/15 - $72.44
52 Week Low
09/5/14 - $37.19
Market Cap
1.8B
Average Volume 10 Days
1.0M
EPS TTM
$4.04
Shares Outstanding
36.5M
EX-Date
--
P/E TM
12.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for LANNETT CO INC (LCI)

Related News

No related news articles were found.

lannett co inc (LCI) Related Businessweek News

No Related Businessweek News Found

lannett co inc (LCI) Details

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. The company provides its products for various medical indications comprising glaucoma, muscle relaxant, migraine, anesthetic, congestive heart failure, thyroid deficiency, dryness of the mouth, gout, bronchospasms, hypertension, and gallstone. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Lioresal, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Lanoxin, Levoxyl/Synthroid, Salagen, Benemid, Brethine, Dyazide, and Actigall brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. It has development and supply agreements with Azad Pharma AG, Aenova of Switzerland, Pharma 2B, the GC Group of Israel, HEC Pharm Group, and Sunshine Lake LLC, as well as with Jerome Stevens Pharmaceuticals, Inc., Cerovene, Symplemed, Inc., and Summit Bioscience LLC. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

502 Employees
Last Reported Date: 08/27/15
Founded in 1942

lannett co inc (LCI) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $555.2K
President
Total Annual Compensation: $280.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $326.5K
Chief Operating Officer
Total Annual Compensation: $356.4K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $286.3K
Compensation as of Fiscal Year 2015.

lannett co inc (LCI) Key Developments

Lannett Company, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015; Provides Earnings Guidance for Fiscal 2016

Lannett Company, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, net sales rose 23% to $99.3 million from $80.6 million in last year's fourth quarter. Operating income grew 37% to $51.0 million from $37.4 million. Net income attributable to Lannett Company increased 44% to $33.9 million, or $0.91 per diluted share, from $23.5 million, or $0.64 per diluted share, for the prior year fourth quarter. Income before income taxes was $51.18 million against $37.57 million a year ago. For the full year, net sales rose 49% to $406.8 million from $273.8 million in the prior year. Operating income was $226.5 million compared with $88.1 million for the prior year. Excluding the JSP contract renewal charge, operating income for the prior-year period was $108.2 million. Net income attributable to Lannett Company was $149.9 million, or $4.04 per diluted share, compared with $57.1 million, or $1.62 per diluted share, for fiscal 2014. Adjusted net income, which excludes the impact of the JSP contract renewal charge equal to $12.6 million after-tax, was $69.7 million, or $1.98 per diluted share, in fiscal 2014. Income before income taxes was $227.42 million against $90.02 million a year ago. Based on current outlook, the company provided financial guidance for the fiscal 2016 full year as follows: Net sales in the range of $425 million to $435 million; Gross margin as a percentage of net sales of approximately 71% to 73%; effective tax rate to be in the range of 34% to 35%; and Capital expenditures to be in the range of $60 million to $70 million, which includes $30 million to continue the partial fit-out of company-owned buildings.

Lannett Company, Inc. Announces the Change of Chief Operating Officer, Effective September 11, 2015

On August 11, 2015, William F. Schreck, the Chief Operating Officer of Lannett Company, Inc., delivered his notice of retirement effective September 11, 2015. Mr. Schreck joined the company in January 2003 and has been Chief Operating Officer since January 2011. In the interim, the responsibilities of the Chief Operating Officer are being transitioned to the company's President, Michael Bogda.

Lannett Company, Inc. to Report Q4, 2015 Results on Aug 25, 2015

Lannett Company, Inc. announced that they will report Q4, 2015 results at 5:00 PM, Eastern Standard Time on Aug 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCI:US $49.87 USD -0.17

LCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ANI Pharmaceuticals Inc $52.00 USD +1.91
Covisint Corp $2.70 USD +0.09
Impax Laboratories Inc $42.40 USD -1.57
Pernix Therapeutics Holdings Inc $4.70 USD +0.10
Sagent Pharmaceuticals Inc $20.04 USD +0.17
View Industry Companies
 

Industry Analysis

LCI

Industry Average

Valuation LCI Industry Range
Price/Earnings 12.4x
Price/Sales 4.4x
Price/Book 3.9x
Price/Cash Flow 12.1x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANNETT CO INC, please visit www.lannett.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.